Want to see REPL full AI Analyst Report?
Top Page
Replimune Group
(NASDAQ:REPL)
Select Model
Select Model
Rating:52Neutral
Price Target:
$11.50
▲(429.95% Upside)
Action:Reiterated
Date:06/29/26
The score is held down primarily by weak financial performance (no revenue, accelerating losses, and heavy cash burn with a shrinking equity base), implying ongoing financing risk. Offsetting this, technicals show a strong uptrend with positive momentum, and corporate events add a constructive near-term catalyst from FDA review acceptance; however, valuation remains constrained by continued losses and no dividend support.
Positive Factors
Regulatory Progress
Acceptance of the RP1 BLA as a complete, Class 1 resubmission with a set action date and advisory committee creates a defined regulatory timeline and formal review pathway. This materially reduces long-term binary uncertainty and, if favorable, would enable transition from clinical-stage to commercial-stage operations.
Negative Factors
No Commercial Revenue
Absence of product revenue means the firm lacks an internal cash-generating engine and remains fully dependent on external financing until commercialization. This structural profile lengthens time to self-sufficiency and increases execution risk if clinical or regulatory setbacks delay approval or launch.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Acceptance of the RP1 BLA as a complete, Class 1 resubmission with a set action date and advisory committee creates a defined regulatory timeline and formal review pathway. This materially reduces long-term binary uncertainty and, if favorable, would enable transition from clinical-stage to commercial-stage operations.
Read all positive factors
Replimune Group Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyReplimune Group (REPL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$933.47M
Dividend YieldN/A
Average Volume (3M)5.31M
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth-9.27%
CountryUS
Employees479
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.38
Shares Outstanding83,945,160
10 Day Avg. Volume3,267,863
30 Day Avg. Volume5,307,876
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$11.00Price Target Upside406.91% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$22.17M
Replimune Group Business Overview & Revenue Model
Company Description
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic c...
How the Company Makes Money
Replimune does not primarily generate revenue from commercial product sales because its lead candidates are in clinical development. The company’s income typically consists of (1) collaboration and licensing-related revenue when it enters partners...
Replimune Group Earnings Call Summary
Earnings Call Date:May 22, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The earnings call provided a positive outlook, highlighting significant regulatory achievements, strong commercial readiness, and financial stability. However, the increase in net loss and operational expenses presents challenges. The overall sentiment is optimistic about RP1's potential launch and market adoption.Positive Updates
Breakthrough Therapy Designation and Priority Review for RP1
RP1 has been recognized as a breakthrough therapy with priority review, with a PDUFA date set for July 22, 2025. The company has completed late-cycle meetings and manufacturing inspections with the FDA, indicating substantial regulatory progress.
Negative Updates
Increased Net Loss
The company's net loss increased to $74.1 million for the fiscal fourth quarter and $247.3 million for the fiscal year ended March 31, 2025, compared to $55.1 million and $215.8 million, respectively, for the prior year.
Read all updates
Q4-2025 Updates
Positive
Negative
Breakthrough Therapy Designation and Priority Review for RP1
RP1 has been recognized as a breakthrough therapy with priority review, with a PDUFA date set for July 22, 2025. The company has completed late-cycle meetings and manufacturing inspections with the FDA, indicating substantial regulatory progress.
Read all positive updates
Company Guidance
During the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call, significant progress was highlighted across regulatory, clinical, and commercial fronts as the company approaches the potential approval and launch of RP1. The product has been recognized as a breakthrough therapy with a priority review and a PDUFA date set for July 22, 2025. The Ignite 3 confirmatory study is underway, with over 100 planned global sites, focusing on overall survival as the primary endpoint. Replimune estimates that approximately 13,000 patients progress on or after PD-1 treatment annually in the U.S., with 80% of these patients potentially eligible for RP1. The company ended the fiscal year with $483.8 million in cash and cash equivalents and anticipates a cash runway into the fourth quarter of 2026. Research and development expenses totaled $189.4 million for the fiscal year, with a net loss of $247.3 million. The company has completed its commercial infrastructure build-out, comprising approximately 60 people, and plans to provide critical services through the Replimune Connect Plus patient support hub.Replimune Group Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
54
Neutral
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.58M |
| EBITDA | -314.49M | -253.92M | -227.77M | -171.72M | -114.41M |
| Net Income | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M |
Balance Sheet | |||||
| Total Assets | 332.39M | 551.33M | 487.72M | 646.59M | 461.19M |
| Cash, Cash Equivalents and Short-Term Investments | 268.89M | 483.80M | 420.67M | 583.39M | 395.65M |
| Total Debt | 28.28M | 76.17M | 75.87M | 60.76M | 32.84M |
| Total Liabilities | 166.23M | 135.49M | 113.21M | 91.30M | 49.96M |
| Stockholders Equity | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M |
Cash Flow | |||||
| Free Cash Flow | -284.57M | -198.94M | -191.13M | -130.32M | -84.52M |
| Operating Cash Flow | -280.34M | -192.25M | -185.47M | -128.05M | -82.18M |
| Investing Cash Flow | 310.84M | -23.80M | 97.20M | -142.50M | -1.81M |
| Financing Cash Flow | 66.29M | 252.40M | 16.28M | 311.30M | 6.60M |
Replimune Group Technical Analysis
Positive
2.17
Price Trends
7.48
Positive
6.90
Positive
7.43
Positive
Market Momentum
1.04
Positive
63.87
Neutral
52.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REPL, the sentiment is Positive. The current price of 2.17 is below the 20-day moving average (MA) of 10.54, below the 50-day MA of 7.48, and below the 200-day MA of 7.43, indicating a bullish trend. The MACD of 1.04 indicates Positive momentum. The RSI at 63.87 is Neutral, neither overbought nor oversold. The STOCH value of 52.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for REPL.
Replimune Group Risk Analysis
Replimune Group disclosed 60 risk factors in its most recent earnings report. Replimune Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Replimune Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $2.51B | -7.16 | -64.21% | ― | 27.23% | -12.53% | |
56 Neutral | $3.81B | -9.46 | -68.97% | ― | 67.38% | 24.05% | |
52 Neutral | $933.47M | -3.29 | -102.69% | ― | ― | -9.27% | |
52 Neutral | $1.13B | -7.60 | -35.33% | ― | ― | 23.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.11B | -4.23 | -161.87% | ― | ― | -6.15% | |
43 Neutral | $250.21M | -6.02 | -38.76% | ― | ― | 15.81% |
* Healthcare Sector Average
REPL
Replimune Group
11.11
0.34
3.16%
AVXL
Anavex Life Sciences
2.70
-8.48
-75.85%
RCUS
Arcus Biosciences
29.96
20.42
214.05%
ORIC
Oric Pharmaceuticals
10.94
-0.51
-4.45%
NRIX
Nurix Therapeutics
24.69
12.02
94.87%
SANA
Sana Biotechnology
3.93
-0.13
-3.20%
Replimune Group Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
Replimune’s RP1 BLA Resubmission Accepted for Review
Positive
Jun 26, 2026
On June 26, 2026, Replimune announced that the U.S. Food and Drug Administration accepted for review the resubmission of its Biologics License Application for RP1, in combination with nivolumab, for advanced melanoma. The FDA classified the filing...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Replimune to Resubmit Priority FDA Filing for RP1
Positive
May 29, 2026
On May 29, 2026, Replimune announced it will shortly resubmit its Biologics License Application to the U.S. Food and Drug Administration for RP1, used in combination with nivolumab, for patients with advanced melanoma. Following what the company d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.